- Home
- TLSI vs SKYE Comparison
TLSI vs SKYE Comparison
Compare TLSI & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- SKYE
- Stock Information
- Founded
- TLSI 2010
- SKYE 2012
- Country
- TLSI United States
- SKYE United States
- Employees
- TLSI N/A
- SKYE N/A
- Industry
- TLSI Medical Specialities
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- TLSI Health Care
- SKYE Health Care
- Exchange
- TLSI Nasdaq
- SKYE Nasdaq
- Market Cap
- TLSI 124.9M
- SKYE 94.0M
- IPO Year
- TLSI N/A
- SKYE N/A
- Fundamental
- Price
- TLSI $4.69
- SKYE $2.73
- Analyst Decision
- TLSI Strong Buy
- SKYE Buy
- Analyst Count
- TLSI 6
- SKYE 6
- Target Price
- TLSI $11.75
- SKYE $18.67
- AVG Volume (30 Days)
- TLSI 36.4K
- SKYE 167.7K
- Earning Date
- TLSI 11-14-2024
- SKYE 02-09-2025
- Dividend Yield
- TLSI N/A
- SKYE N/A
- EPS Growth
- TLSI N/A
- SKYE N/A
- EPS
- TLSI N/A
- SKYE N/A
- Revenue
- TLSI $26,891,000.00
- SKYE N/A
- Revenue This Year
- TLSI $60.96
- SKYE N/A
- Revenue Next Year
- TLSI $53.65
- SKYE N/A
- P/E Ratio
- TLSI N/A
- SKYE N/A
- Revenue Growth
- TLSI 67.90
- SKYE N/A
- 52 Week Low
- TLSI $3.50
- SKYE $2.25
- 52 Week High
- TLSI $10.42
- SKYE $19.41
- Technical
- Relative Strength Index (RSI)
- TLSI 51.68
- SKYE 37.40
- Support Level
- TLSI $4.72
- SKYE $2.31
- Resistance Level
- TLSI $5.32
- SKYE $3.04
- Average True Range (ATR)
- TLSI 0.31
- SKYE 0.30
- MACD
- TLSI 0.01
- SKYE 0.07
- Stochastic Oscillator
- TLSI 47.52
- SKYE 44.68
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.